HOME >> MEDICINE >> NEWS
New system for reporting toxicity burden of cancer treatment

A new system for reporting the relative toxicity burden of different cancer treatments is proposed in an Article published early Online and in the July edition of The Lancet Oncology.

Professor Andy Trotti, H Lee Moffitt Cancer Centre, University of South Florida, Tampa, Florida, USA and colleagues assessed deficiencies in established methods for summarising adverse events, and devised their new method.

The new system, named TAME, places traditional adverse-event data into three concise risk domains: short term toxicity (T), adverse long term effects (A) and mortality risk (M), which are calculated for each treatment programme to generate an end-result (E) summary index.

The authors say: "This is an entirely new concept in risk assessment. It was specifically designed for the evaluation of cancer treatments. Traditional safety reporting methods were designed for low-risk non-cancer treatments, and are simply overwhelmed by the amount of toxicity data generated in cancer treatment programs. Thus, a new way to look at risk that is more relevant to oncology is needed."

Despite being in the early stages of development, TAME has managed to identify differences of up to 500% in acute toxicity burden between certain cancer treatments. Established methods only detected a 170% difference in short term effects between those treatments. Established summary methods were also found to disregard a large amount of important information, and only permit comparing rates of each type of side effect (in cancer treatments there are dozens of types), whereas TAME includes all types of severe side effects, and considers their relative frequency, using a concise scoring system. However there was little difference between TAME and established methods in detecting the variation of risk in events that happened late in treatment.

TAME aims to provide a "side-effects" summary index for each treatment, so that the "total toxicity price" of
'"/>

Contact: Professor Andy Trotti
Andy.Trotti@moffitt.org
813-335-5231
Lancet
30-May-2007


Page: 1 2

Related medicine news :

1. WPI wins $1M to develop system to locate and monitor emergency workers in buildings
2. U of M researchers assess effectiveness of computerized physician order entry system
3. STAMP system can help professionals to identify potentially violent individuals
4. Doctors, engineers develop new wireless system to detect esophageal reflux
5. A pioneering system allows autistic children to communicate with their environment
6. Transplanting human gut bugs into mice helps understanding of metabolic system
7. Scientists develop method to track immune system enzyme in live animals
8. Vitamin D supplements may offer cheap and effective immune system boost against TB
9. New update of international health system comparisons: US continues to lag on most measures
10. DALYs system for measuring disability
11. Scientists equip bacteria with custom chemo-navigational system

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New system for reporting toxicity burden cancer treatment

(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative and ... to treat specific body parts and muscle groups. , ... to use patented cold therapy machine with the innovative IsoTube ... muscle injuries. IsoComforter has become the industry leader in ...
(Date:1/22/2015)... January 22, 2015 Payday lending practices ... communities and cause financial distress to the states that ... at Howard University’s Center on Race and Wealth. , ... economic activity, payday loans at the same time substantially ...
(Date:1/22/2015)... 2015 As interest in the value of ... momentum worldwide, Rev. Eric J. Hall , president and ... (HCCN), will be the keynote speaker on January 27 at ... health system. , The conference, “Hope and Resilience: Innovative and ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Compare-autoinsurance.org has released a ... insured by an auto insurance policy . , Some ... policy. Clients should check the newly released blog post to see ... cars and dangerously damaged vehicles are some of the cars that ...
(Date:1/22/2015)... VA (PRWEB) January 22, 2015 Step ... power at the Science Museum of Virginia. Wicked Plants, ... , Wicked Plants unearths 75 poisonous, carnivorous and diabolical ... through each room to uncover the biochemical, physical and ...
Breaking Medicine News(10 mins):Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2
(Date:1/23/2015)... and DUBLIN , Jan. 23, 2015  Immune ... KRS Global Biotechnology, Inc. for the compounding, packaging and distributing ... shipment in the United States . ... Facility capable of compounding naltrexone tablets in various strengths for ...
(Date:1/23/2015)...  HyGreen, Inc., a leader in hand hygiene monitoring, today ... a subsidiary of Ascendis Health Limited, in ... hundreds of millions of patients around the world are ... from patient to patient via the unwashed hands of ...
(Date:1/23/2015)...  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that the number ... lead compound, LB‑100, is being conducted, has been expanded from ... , M.D., the founder and President of Lixte, said that, ... single site. Accrual of patients, however, was slower than projected. ...
Breaking Medicine Technology:Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
Cached News: